Page 1: Executive summary

Market Overview

Page 2: Global Oncology Pharmaceuticals Market - Overview, Size & Growth (Value: 2007-13e),

Page 3:Indian Oncology Pharmaceuticals Market-Overview ,Size, Growth(Value:2010-2016e),Increase in cancer cases (2010-2020e)

Page 4:Cancer map in India

Page 5 and 6: Import and Export of oncology pharmaceuticals- Size & Growth (Value: 2006-2010), Region Wise (2009 and 2010)

Drivers & Challenges

Page 7: Summary

Page 8-12: Drivers

Page13-14: Challenges

Government initiatives

Page 15: Summary

Page 16-20: Key Government initiatives

Drug regulation and patents

Page 21: Phases of clinical trials

Page 22-23: Drug regulations

Page 24-25: List of patent approvals

Competition:

Page 26-34: Major domestic players

Page 35-40: Major domestic players

Page 41: Recent Developments

Oncology pharmaceuticals market in India, a leading segment of the overall pharmaceuticals market is the fourth largest in volume and eighth largest in value in the global market. Since cancer is the second largest cause of death in the country, the Indian market is characterized by a huge demand for cancer drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the number of cancer cases, specially in lung cancer and breast cancer cases; changes in the cancer treatment scenario, development of alternative cancer therapies, increased cancer health insurance coverage and increasing amount of foreign direct investment (FDI) is helping the market to grow. The Indian Government, on its part is taking initiatives to work out public-private partnership projects (PPP) and reduce the essential drug prices. The market is expected to exhibit steady growth over the next few years.

The report begins with the market overview section which provides an insight into the global market, highlighting the market size and growth. It then moves onto the Indian market, with a focus on market size and growth. It also provides import and export figures of cancer drugs in India in terms of value. Regional break-up of the imports and exports have been included.

An analysis of the drivers explains the factors for growth of the industry including increasing cancer cases, changes in the treatment scenario, development of alternative cancer therapies, increasing FDI and increase in the number of cancer health insurances. The key challenges include increased competition, drug patent problems and drug portfolio management problems.

The government initiatives section highlights the PPP R&D projects started in the country. It also analyses the various initiatives undertaken to reduce prices of cancer drugs, the various cancer control programmes implemented and the changes in the custom duty structure.

A brief overview of the drug regulations and patents is presented in the next section. It focuses the different stages of clinical trial that a drug must pass through. Drug regulations in India and drugs approved for marketing have been provided. The section also provides a list of important patent approvals.

The competition section provides an overview of the competitive landscape in the industry. It includes a brief profile of the major players in the market along with their financials. It also includes the latest developments in the industry.